Aura Biosciences, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Aura Biosciences, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($106.19M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($86.92M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($76.41M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($58.76M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($35.25M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($22.21M) | Mar 23, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($112.79M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($96.12M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($84.99M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($60.30M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($35.25M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($22.21M) | Mar 23, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $90.30M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $73.30M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $65.23M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $42.24M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $25.16M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.04M | Mar 23, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($84.74M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($79.81M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($63.85M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($54.60M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($32.41M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($24.32M) | Mar 23, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.25M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $709.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.09M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.13M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $771.0K | Mar 23, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $169.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $182.50M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $255.08M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $223.94M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $160.03M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $22.10M | Mar 23, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $30.53M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $29.23M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $28.35M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $7.72M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.74M | Mar 23, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $136.91M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $151.97M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $225.85M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $195.58M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $152.32M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | ($108.71M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | ($87.41M) | Mar 23, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($480.42M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($374.23M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($287.31M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($210.90M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($152.14M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($116.89M) | Mar 23, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.52M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $31.69M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $41.06M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $121.58M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $149.06M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $17.39M | Mar 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (8) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 63.59M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 50.00M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 49.35M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 37.77M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 29.21M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 381,123 | Mar 23, 2022 |